Transcriptomics

Dataset Information

0

ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE132617 | GEO | 2020/06/12

REPOSITORIES: GEO

Json Xml

Similar Datasets

Methylation profiling ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [methylation 450K]
2020-06-12 | GSE132615 | GEO
Transcriptomics ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [gene expression]
2020-06-12 | GSE132614 | GEO
Methylation profiling ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [methylation 850K]
2020-06-12 | GSE132616 | GEO
Unknown ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer.
| S-EPMC8263635 | biostudies-literature
Genomics ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway
| PRJNA548537 | ENA
Genomics ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [gene expression]
| PRJNA548639 | ENA
Genomics ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [methylation 450K]
| PRJNA548633 | ENA
Genomics ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [methylation 850K]
| PRJNA548634 | ENA
Unknown WTD Attenuating Rheumatoid Arthritis <i>via</i> Suppressing Angiogenesis and Modulating the PI3K/AKT/mTOR/HIF-1α Pathway.
| S-EPMC8502817 | biostudies-literature
Unknown HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer.
| S-EPMC8210559 | biostudies-literature